Internal Application No
PCT/IB2004/004115

1 .		FC1/	182004/004115
A. CLASSI IPC 7	IFICATION OF SUBJECT MATTER C12Q1/68		
According t	o International Patent Classification (IPC) or to both national classifica	ilion and IPC	
B. FIELDS	SEARCHED		
Minimum de IPC 7	ocumentation searched (classification system followed by classification ${\tt C12Q}$	on symbols)	
Documenta	tion searched other than minimum documentation to the extent that so	uch documents are included in th	e fields searched
Electronic o	data base consulted during the International search (name of data base	se and, where practical, search to	erms used)
EPO-In	ternal, WPI Data, PAJ, BIOSIS, EMBAS	E, CHEM ABS Data,	EMBL
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.
X	PASTINEN T ET AL: "Multiplex, fluorescent, solid-phase miniseque for efficient screening of DNA se variation"	quence	18
	CLINICAL CHEMISTRY, AMERICAN ASSO FOR CLINICAL CHEMISTRY. WINSTON, vol. 42, no. 9, 1996, pages 1391- XP002126144 ISSN: 0009-9147	US,	
Y	page 1392, left-hand column; tabl	e 1	1-8,19, 20
X	WO 00/65088 A (AMERSHAM PHARM BIO ULFENDAHL PER JOHAN (SE); WONG KI (S) 2 November 2000 (2000-11-02) claims 12,14,21		18
Y	the whole document		1-8,19,
•			20
		/	
X Fur	ther documents are listed in the continuation of box C.	X Patent family members	are listed in annex.
"A" docum	ent defining the general state of the art which is not dered to be of particular relevance	cited to understand the prin- invention	onflict with the application but ciple or theory underlying the
filing of the country	date ent which may throw doubts on priority claim(s) or	involve an inventive step wt "Y" document of particular releva	or cannot be considered to nen the document is taken alone ance; the claimed invention
*O* docum other *P* docum	nent referring to an oral disclosure, use, exhibition or means the	document is combined with	olve an inventive step when the one or more other such docu- eing obvious to a person skilled
	actual completion of the international search	Date of mailing of the interna	
	11 March 2005	-	07. 2005
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hagenmaier,	s

# BEST AVAILABLE COPY

# **INTERNATIONAL SEARCH REPORT**

Internal Application No PCT/IB2004/004115

					PC1/1B200	4/ 004115
CONSIDE	DERED TO BE R	RELEVANT				
nt, with indi	dication, where a	appropriate, of t	ne relevant passaç	jes		Relevant to claim No.
yping ive to " AL CHE no. 2 er 200	o hybrid EMISTRY.	spectronization-l 1 NOV 20 -11-01),	netry: an based typi 000,	ng		1-8, 18-20
03-270 e docu						9,12,13
e docu						, 12,13
typing MUNOLO no. S 008032 NNUAL FOR HI	platform g" .0GY, Supplemen 2510 MEETING HISTOCOMP S; LAKE 1 10-14, 20	m for high nt 2, 200 OF THE A ATIBILIT BUENA VI	AMERICAN			1-8, 18-20
;						9,12,13
DE POLIETRY" CTROME W YORK	METRY REV RK, NY, U 6, Novem 3, XP0090	SMS BY MA IEWS, JO S, ber 2002				1-8, 18-20
e docu						9,12,13
through ACIDS no. 1	ighput." 5 RESEARC 19, 02 (2002-	H. 1 OCT	haplotypin 2002, page e96,	<b>ig</b>		1-8, 18-20
e docu						9,12,13
PHISMS ON/ION OMMUNION LONDON OMS ON OMS ON	NOTYPING BY MATR DNIZATION CATIONS DN, GB, 12, 9 Ma 272, XPOO	SINGLE NIX-ASSIS MASS SPIN MASS	THE GOOD UCLEOTIDE TED LASER ECTROMETRY SPECTROMET	RY,		1-8, 18-20
951-419 le docu			-/			9,12,13
e docu				-/	-/	-/

# BEST AVAILABLE COPY

# **INTERNATIONAL SEARCH REPORT**

Internation No
PCT/IB2004/004115

<u> </u>		PCT/IB2004/004115
<u> </u>	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SAUER SASCHA ET AL: "Genotyping single-nucleotide polymorphisms by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry."  JOURNAL OF CHROMATOGRAPHY. B, ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 25 DEC 2002, vol. 782, no. 1-2, 25 December 2002 (2002-12-25), pages 73-87, XP002287585 ISSN: 1570-0232	1-8, 18-20
A	the whole document	9,12,13
Y	WO 02/08462 A (LECHNER DORIS ; GUT IVO GLYNNE (FR); CT NAT DE GENOTYPAGE (FR)) 31 January 2002 (2002-01-31)	1-8, 18-20
Α.	the whole document	9,12,13
Y	ROZEMULLER: "Reference panels for sequence based typing: Selection criteria for HLA-A and HLA-B" 2000, , XP002287586 ISBN: 0-945278-02-0 Retrieved from the Internet: URL:http://www.ihwg.org/tmanual/TMcontents .htm> 'retrieved on 2004-07-05!	1-8, 18-20
Α	Chapter 1-B	9,12,13
Y A	WO 02/18659 A (HAPLOGEN LLC ; LIU XIANGJUN (US)) 7 March 2002 (2002-03-07) the whole document	1-8, 18-20 9,12,13
Y A	US 5 451 512 A (APPLE RAYMOND J ET AL) 19 September 1995 (1995-09-19) the whole document	1-8, 18-20 9,12,13

International application No.

PCT/IB2004/004115

Вох	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1.	With inven	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, the international search was carried out on the basis of:
	a.	type of material  X a sequence listing table(s) related to the sequence listing
	b.	format of material  X in written format  X in computer readable form
	c.	time of filing/furnishing  Contained in the international application as filed  filed together with the international application in computer readable form  furnished subsequently to this Authority for the purpose of search
2.		In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Additi	onal comments:
i i		

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  .
Claims Nos.:     because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box iii Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:  claims 1-8, 18-20 (all partially), 9, 12, 13 (completely)
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1 : claims 1-8, 18-20 (all partially), 9,12,13
 (completely)

Method for HLA typing of HLA-A by the unambiguous determination of short DNA sequence elements at positions 98, 414,539,282,571,368,256,292,238 and 270 simultaneously on both parental alleles at a selected number of positions in HLA -A, comprised of the steps for each position a) hybridising a combination of oligonucleotides complementary to all known sequence variants to a DNA strand upstream of a given position b) carrying out a primer extension reaction with at least one of the four dNTP substrates substituted by a terminating analog c) analysing the products by mass spectrometry, with the resulting masses allowing unambiguous identification of the used primers and added bases; kit for the implementation of such method: use of such method for screening of tissue donors.

Invention 2: 1-8, 18-20 (all partially), 10,14,15 (completely)

Method for HLA typing of HLA-B by the unambiguous

determination of short DNA sequence elements at positions 539,419,559,412,272,362,302,363,206 and 369 simultaneously on both parental alleles at a selected number of positions in HLA-B, comprised of the steps for each position a) hybridising a combination of oligonucleotides complementary to all known sequence variants to a DNA strand upstream of a given position

b) carrying out a primer extension reaction with at least one of the four dNTP substrates substituted by a terminating analog

c) analysing the products by mass spectrometry, with the resulting masses allowing unambiguous identification of the used primers and added bases; kit for the implementation of such method; use of such method for screening of tissue donors.

Invention 3: claims 1-8, 18-20 (all partially), 11,16,17
 (completely)

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Method for HLA typing of HLA-DRB1 by the unambiguous determination of short DNA sequence elements at positions 125,196,197,227,261,286,299,308,341 and 345 simultaneously on both parental alleles at a selected number of positions in HLA-DRB1, comprised of the steps for each position

- a) hybridising a combination of oligonucleotides complementary to all known sequence variants to a DNA strand upstream of a given position
- b) carrying out a primer extension reaction with at least one of the four dNTP substrates substituted by a terminating analog
- c) analysing the products by mass spectrometry, with the resulting masses allowing unambiguous identification of the used primers and added bases; kit for the implementation of such method; use of such method for screening of tissue donors.

Inventions 4-246: claim 21 (partially)

Invention 4:

Use of the primer with Seq.ID 1 to carry out HLA typing. ..ibidem for inventions 5-246, i.e. each of the 242 primers listed in table IV,V and VI.

Information on patent family members

Internation No
PCT/IB2004/004115

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0065088	Α	02-11-2000	AU	5062500 A	10-11-2000
			WO	0065088 A2	02-11-2000
WO 0208462	Α	31-01-2002	EP	1176212 A1	30-01-2002
			ΑU	8435101 A	05-02-2002
			CA	2417201 A1	31-01-2002
			EP	1303638 A1	23-04-2003
			WO	0208462 A1	31-01-2002
			US	2004053260 A1	18-03-2004
WO 0218659	Α	07-03-2002	AU	8917701 A	13-03-2002
			CA	2421078 A1	07-03-2002
			CN	1501982 A	02-06-2004
			JP	2004520812 T	15-07-2004
			WO	0218659 A2	07-03-2002
			US	2003082549 A1	01-05-2003
US 5451512	Α	19-09-1995	AU	2748592 A	06-05-1993
			BR	9204280 A	11-05-1993
			CA	2081582 A1	06-05-1993
			CN	1073484 A	23-06-1993
			EP	0540997 A1	12-05-1993
			FΙ	924999 A	06-05-1993
			JP	8066197 A	12-03-1996
			NO	924246 A	06-05-1993
			NZ	244924 A	26-07-1994
			ZA	9208374 A	13-05-1993